Get informed when a big investor buys or sells
+ FollowOvervalued by 113.1% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $119.51 Million |
|---|---|
| Enterprise Value | $131.27 Million |
| Earnings per Share | $-0.18 |
| Beta | 0.74 |
| Outstanding Shares | 103,923,100 |
| P/E Ratio | -4.63 |
|---|---|
| PEG | 0.09 |
| Price to Sales | - |
| Price to Book Ratio | -1.15 |
| Enterprise Value to Revenue | 27.86 |
| Enterprise Value to EBIT | -4.48 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.13 |
| Debt to Equity | -0.88 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Scancell Holdings plc is a clinical-stage biopharmaceutical firm focused on discovering and developing innovative vaccine and antibody treatments. Its mission is to address significant unmet medical needs in both cancer and infectious di...